采用5-氟尿嘧啶-链脲霉素与5-氟尿嘧啶-达卡巴嗪交替联合方案治疗晚期甲状腺髓样癌。降钙素瘤研究小组（GETC）。
Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
作者信息
Schlumberger M, Abdelmoumene N, Delisle M J, Couette J E
机构信息
Institut Gustave-Roussy, Villejuif, France.
出版信息
Br J Cancer. 1995 Feb;71(2):363-5. doi: 10.1038/bjc.1995.73.
Abstract
Combinations of 5-fluorouracil (5-FU) and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 11 long-term stabilizations were observed. No unexpected toxicity occurred.
摘要
对20例转移性甲状腺髓样癌患者交替给予5-氟尿嘧啶（5-FU）与链脲佐菌素及5-FU与达卡巴嗪联合治疗。观察到3例部分缓解和11例长期病情稳定。未出现意外毒性反应。
相似文献
1
Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).采用5-氟尿嘧啶-链脲霉素与5-氟尿嘧啶-达卡巴嗪交替联合方案治疗晚期甲状腺髓样癌。降钙素瘤研究小组（GETC）。
Br J Cancer. 1995 Feb;71(2):363-5. doi: 10.1038/bjc.1995.73.
2
Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).采用阿霉素-链脲佐菌素与5-氟尿嘧啶-达卡巴嗪交替联合方案治疗晚期甲状腺髓样癌。降钙素瘤研究组（GETC）。
Br J Cancer. 2000 Sep;83(6):715-8. doi: 10.1054/bjoc.2000.1314.
3
Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.联合放射免疫化疗改善裸鼠模型中甲状腺髓样癌的治疗：阿霉素增强放射性标记抗体对放射抗性肿瘤类型的治疗效果。
Cancer Res. 1997 Dec 1;57(23):5309-19.
4
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
Ann Oncol. 1994 Oct;5(8):763-5. doi: 10.1093/oxfordjournals.annonc.a058984.
5
[Causes of death in patients with medullary cancer of the thyroid. GETC. Groupe d'Etude des Tumeurs à Calcitonine].[甲状腺髓样癌患者的死因。GETC。降钙素瘤研究组]
Presse Med. 1996 Nov 30;25(37):1819-22.
6
Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs á Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons.IIa型多发性内分泌腺瘤病中的原发性甲状旁腺功能亢进症：法国多中心回顾性研究。降钙素肿瘤研究组（GETC，法国降钙素肿瘤研究组），法国内分泌外科医生协会。
World J Surg. 1996 Sep;20(7):808-12; discussion 812-3. doi: 10.1007/s002689900123.
7
[Medullary thyroid carcinoma: evolution of concepts].
Arch Anat Cytol Pathol. 1998;46(1-2):100-11.
8
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.甲状腺髓样癌生存及生化治愈的预后因素：899例患者的结果。GETC研究组。降钙素肿瘤研究组
Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73. doi: 10.1046/j.1365-2265.1998.00392.x.
9
Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.甲状腺髓样癌：包括2A型多发性内分泌腺瘤病和2B型多发性内分泌腺瘤病综合征。
J Surg Oncol. 2005 Mar 1;89(3):122-9. doi: 10.1002/jso.20184.
10
Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).术前降钙素水平可预测甲状腺髓样癌的肿瘤大小及术后降钙素水平恢复正常。降钙素瘤研究组（GETC）。
J Clin Endocrinol Metab. 2000 Feb;85(2):919-22. doi: 10.1210/jcem.85.2.6556.
引用本文的文献
1
Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.甲状腺髓样癌患者的长期随访
Recent Results Cancer Res. 2025;223:267-291. doi: 10.1007/978-3-031-80396-3_11.
2
Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.甲状腺髓样癌的分子影像及相关治疗选择：现状与未来机遇。
Rev Endocr Metab Disord. 2024 Feb;25(1):187-202. doi: 10.1007/s11154-023-09836-y. Epub 2023 Sep 16.
3
Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer.晚期/转移性甲状腺髓样癌患者的诊断特征、治疗模式及临床结局
Thyroid Res. 2022 Feb 12;15(1):2. doi: 10.1186/s13044-021-00119-9.
4
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.凡德他尼治疗晚期甲状腺髓样癌的真实世界多中心经验。
Endocrinol Metab (Seoul). 2020 Sep;35(3):587-594. doi: 10.3803/EnM.2020.687. Epub 2020 Sep 22.
5
Using molecular dynamics simulation to explore the binding of the three potent anticancer drugs sorafenib, streptozotocin, and sunitinib to functionalized carbon nanotubes.利用分子动力学模拟探索三种强效抗癌药物索拉非尼、链脲佐菌素和舒尼替尼与功能化碳纳米管的结合。
J Mol Model. 2019 May 14;25(6):159. doi: 10.1007/s00894-019-4024-5.
6
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.伊马替尼、达卡巴嗪和卡培他滨用于晚期内分泌癌的I期研究。
BMC Cancer. 2014 Aug 2;14:561. doi: 10.1186/1471-2407-14-561.
7
Medical management of metastatic medullary thyroid cancer.转移性甲状腺髓样癌的医学治疗。
Cancer. 2014 Nov 1;120(21):3287-301. doi: 10.1002/cncr.28858. Epub 2014 Jun 18.
8
2012 European thyroid association guidelines for metastatic medullary thyroid cancer.2012 年欧洲甲状腺协会转移性甲状腺髓样癌治疗指南。
Eur Thyroid J. 2012 Apr;1(1):5-14. doi: 10.1159/000336977. Epub 2012 Mar 28.
9
Immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma.犬甲状腺癌潜在治疗靶点的免疫组化表达
J Vet Intern Med. 2014 Mar-Apr;28(2):564-70. doi: 10.1111/jvim.12330. Epub 2014 Feb 24.
10
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.帕唑帕尼治疗转移性和进展性甲状腺髓样癌的多中心 2 期临床试验：MC057H。
J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25.
本文引用的文献
1
Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine.
Cancer. 1994 Jan 15;73(2):432-6. doi: 10.1002/1097-0142(19940115)73:2<432::aid-cncr2820730231>3.0.co;2-k.
2
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
3
Therapy of malignant APUD cell tumors. Effectiveness of DTIC.
Cancer. 1983 Mar 1;51(5):790-4. doi: 10.1002/1097-0142(19830301)51:5<790::aid-cncr2820510507>3.0.co;2-3.
4
Doxorubicin plus cisplatin in the treatment of apudomas.多柔比星联合顺铂治疗APUD瘤
Cancer. 1985 Jun 1;55(11):2634-7. doi: 10.1002/1097-0142(19850601)55:11<2634::aid-cncr2820551117>3.0.co;2-t.
5
Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.阿霉素联合顺铂用于晚期甲状腺癌的II期评估：一项东南癌症研究组试验
Cancer Treat Rep. 1986 Mar;70(3):405-7.
6
A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.
Cancer. 1985 Nov 1;56(9):2155-60. doi: 10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e.
7
Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil.转移性甲状腺髓样癌。对达卡巴嗪和5-氟尿嘧啶联合化疗完全缓解。
Cancer. 1988 Nov 1;62(9):1899-903. doi: 10.1002/1097-0142(19881101)62:9<1899::aid-cncr2820620905>3.0.co;2-c.
8
Chemotherapy for thyroid cancer.甲状腺癌的化疗
Radiother Oncol. 1987 Nov;10(3):187-94. doi: 10.1016/s0167-8140(87)80004-x.
9
Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy.转移性非间变性甲状腺癌的化疗：古斯塔夫-鲁西研究所的经验
Tumori. 1990 Oct 31;76(5):480-3. doi: 10.1177/030089169007600513.
10
Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide.用生长抑素类似物奥曲肽对转移性甲状腺髓样癌进行长期治疗。
Clin Endocrinol (Oxf). 1990 Aug;33(2):261-9. doi: 10.1111/j.1365-2265.1990.tb00490.x.
Zotero 插件